within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF11_Sugemalimab;
model Sugemalimab 
   extends Pharmacolibrary.Drugs.ATC.L.L01FF11;

  annotation(Documentation(
    info ="<html><body><p>Sugemalimab is a humanized monoclonal antibody targeting PD-L1, used as an immune checkpoint inhibitor in cancer therapy, particularly for non-small cell lung cancer (NSCLC). It is approved for medical use in China and is undergoing further clinical investigation globally.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters in adult patients with advanced solid tumors and lymphoma, as assessed in clinical trial population.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Sugemalimab;
